What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.
Am J Med. 2019 Mar 20;:
Authors: Ferraro RA, Nass CM, Dudum R, Blumenthal RS, Sarkar S
The treatment of cardiovascular disease in patients with diabetes has seen a sea-change in recent years with the development of novel anti-hyperglycemic agents. The impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), two medication classes introduced in the U.S in the wake of increased scrutiny by the U.S. Food and Drug Administration on cardiovascular disease and anti-hyperglycemic agents, highlight this progression. In recent trials, SGLT2 inhibitors have demonstrated significant reductions in heart failure admissions in patients with established cardiovascular disease and those at risk of cardiovascular disease, as well as significant reductions in major adverse cardiovascular events for those with established cardiovascular disease. GLP-1 RAs have exhibited consistent reductions in major adverse cardiovascular events for patients with established cardiovascular disease. These developments have led the 2019 American Diabetes Association guidelines to recommend considering each patient's cardiovascular history when selecting anti-hyperglycemic agents. The goal of this paper is to review recent updates and provide relevant strategies for providers on SGLT2 and GLP-1 RAs in treating cardiovascular disease in patients with diabetes.
PMID: 30904510 [PubMed - as supplied by publisher]